Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

This phase II trial studies how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

recurrent ovarian cancer
monoclonal antibodies
measurable disease
tumor cells
pembrolizumab
  • 4 views
  • 11 Feb, 2022
  • 1 location
Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase II trial investigates how well pembrolizumab and carboplatin work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of …

  • 0 views
  • 07 Oct, 2022
  • 1 location
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

The purpose of this study is to evaluate the role of cytoreductive surgery and Niraparib maintenance in platinum-sensitive secondary recurrent ovarian cancer.

fallopian tube cancer
maintenance therapy
niraparib
recurrent disease
gemcitabine
  • 11 views
  • 21 Feb, 2022
  • 1 location
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving …

  • 1 views
  • 03 Nov, 2021
  • 1 location
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancers

SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.

doxorubicin
measurable disease
bevacizumab
cancer chemotherapy
line of therapy
  • 0 views
  • 11 Oct, 2022
  • 3 locations
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery (EHTASEOCCS)

This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy of hyperthermic intraperitoneal chemotherapy in the treatment of advanced-stage epithelial ovarian cancer after cytoreductive surgery. Median recurrence-free survival is the primary end points of this project.

cytoreductive surgery
immunostimulant
paclitaxel
renal function tests
docetaxel
  • 3 views
  • 17 Feb, 2022
  • 5 locations
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

The purpose of this study is to answer the fundamental question, should the physicians choose Surgery or Chemotherapy (SOC-2) in advanced ovarian cancer?

paclitaxel
renal function tests
serum ca-125
carboplatin
peritoneal carcinoma
  • 505 views
  • 22 Oct, 2021
  • 7 locations
Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients

This is a single arm phase II, multicenter study evaluating Pembrolizumab in recurrent platinum resistant CPS score >1 positive ovarian, Fallopian tube and primary peritoneal cancer patients.

measurable disease
cancer antigen 125
pembrolizumab
peritoneal cancer
fallopian tube
  • 0 views
  • 26 Dec, 2021
  • 1 location
A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib as Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients (Newton)

This study evaluates whether the adoption of the RADAR dosing strategy could further reduce treatment related toxicities improving the safety profile of niraparib.

Accepts healthy volunteers
neutrophil count
niraparib
cancer of the ovary
direct bilirubin
  • 0 views
  • 10 Oct, 2022
  • 7 locations
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

This phase II trial compares copanlisib and olaparib to standard of care chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous platinum-based chemotherapy (platinum resistant) and that has come back (recurrent). Copanlisib may stop the growth of tumor cells by blocking …

  • 0 views
  • 07 Oct, 2022
  • 1 location